Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 257 results for radiotherapy

  1. Cryotherapy for recurrent prostate cancer (HTG71)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

  2. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

  3. Kidney cancer: diagnosis and management (NG256)

    This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.

  4. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  5. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (HTG305)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

  6. Minimally invasive radical hysterectomy for early stage cervical cancer (HTG565)

    Evidence-based recommendations on minimally invasive radical hysterectomy for early stage cervical cancer. This involves removing the uterus, cervix, upper vagina and some lymph nodes.

  7. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and...

  8. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

  9. High-intensity focused ultrasound for prostate cancer (HTG70)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

  10. Cryotherapy as a primary treatment for prostate cancer (HTG91)

    Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.

  11. Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

    Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.

  12. Photodynamic therapy for advanced bronchial carcinoma (HTG54)

    Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

  13. High dose rate brachytherapy for carcinoma of the cervix (HTG104)

    Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.

  14. Managing glioma: management of IDH wildtype grade II glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH wildtype grade II glioma?

    glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH...

  15. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.